920 results on '"Brouwer, Elisabeth"'
Search Results
2. Diagnostic delay in patients with giant cell arteritis: results of a fast-track clinic
3. The immune pathology of bursitis in rheumatic inflammatory diseases, degenerative conditions and mechanical stress: A systematic review
4. Advances in PET Imaging of Large Vessel Vasculitis: An Update and Future Trends
5. Effect of DMARDs on the immunogenicity of vaccines
6. Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics
7. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
8. Large vessel giant cell arteritis
9. Impaired IL-6-induced JAK-STAT signaling in CD4+ T cells associates with longer treatment duration in giant cell arteritis
10. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis
11. Monocyte subsets and monocyte-related chemokines in Takayasu arteritis
12. Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study
13. Humoral SARS–CoV‐2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster
14. Cytokine producing B-cells and their capability to polarize macrophages in giant cell arteritis
15. Phage display sequencing reveals that genetic, environmental, and intrinsic factors influence variation of human antibody epitope repertoire
16. Positron Emission Tomography Imaging in Vasculitis
17. Large Vessel Vasculitis
18. Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica
19. Altered Plasma Levels and Tissue Expression of Fibroblast Activation Protein Alpha in Giant Cell Arteritis.
20. Comment on: Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Reply
21. Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study
22. A direct comparison in diagnostic performance of CDUS, FDG-PET/CT and MRI in patients suspected of giant cell arteritis
23. Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica
24. PET imaging in vasculitis
25. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial
26. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective
27. Mechanisms of Naive CD4+ T Cell Maintenance in the Elderly and Its Implications for Autoimmunity
28. Comparing Diagnostic Performance of Short and Long [18F]FDG-PET Acquisition Times in Giant Cell Arteritis
29. Increased Diagnostic Accuracy of the Labial Gland Biopsy in Primary Sjögren Syndrome When Multiple Histopathological Features Are Included.
30. Autoantibody Profiling and Anti-Kinesin Reactivity in ANCA-Associated Vasculitis
31. Increased diagnostic accuracy of the labial gland biopsy in primary Sjögren's syndrome when multiple histopathological features are included
32. Role of 18F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica
33. ANCA-associated vasculitis
34. Diagnostic delay in patients with giant cell arteritis: results of a fast-track clinic
35. Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls
36. Humoral SARS–CoV‐2 Vaccine Responses in Patients With Giant Cell Arteritis and Polymyalgia Rheumatica: Decay After Primary Vaccination and Effects of the Booster
37. Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
38. Indication of Activated Senescence Pathways in the Temporal Arteries of Patients With Giant Cell Arteritis
39. Self-Reported Systemic Sclerosis-Related Symptoms Are More Prevalent in Subjects with Raynaud’s Phenomenon in the Lifelines Population: Focus on Pulmonary Complications
40. Evidence for increased interferon type I activity in CD8+ T cells in giant cell arteritis patients
41. Salivary gland 18F-FDG-PET/CT uptake patterns in Sjögren's syndrome and giant cell arteritis patients
42. Effect of age and sex on immune checkpoint expression and kinetics in human T cells
43. Comparing Diagnostic Performance of Short and Long [ 18 F]FDG-PET Acquisition Times in Giant Cell Arteritis.
44. Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma
45. Ultrasound for the Detection of Inflammatory Abdominal Aortic Aneurysms: A Case and Validation Series
46. Role of18F-FDG PET/CT in Large Vessel Vasculitis and Polymyalgia Rheumatica
47. Mucosal-associated invariant T cells in patients with axial spondyloarthritis
48. Autoantibody Profiling and Anti-Kinesin Reactivity in ANCA-Associated Vasculitis
49. Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica
50. Identification of new risk loci and pathways involved in GCA pathogenesis by a genome-wide.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.